- Premarin Facts & Opinion - Project AWARE
- Premarin Conjugated oestrogens Tablets Drug / Medicine.
- The Strange Case of Premarin - ACS Publications
- Premarin the intruing history of a controverisal drug. - NCBI
Premarin Facts & Opinion - Project AWARE
Isolated from pregnant mares, the complex mixture now known to contain more than 50 estrogens was introduced in 1942 by Wyeth Ayerst (now a division of American Home Products, based in Philadelphia) as a treatment for hot flashes and other symptoms of menopause.
Premarin Conjugated oestrogens Tablets Drug / Medicine.
Conjugated estrogens belong to the class of medications known as estrogen replacement therapy.
The Strange Case of Premarin - ACS Publications
Estrogen is a female hormone that is produced by the ovaries.
Premarin the intruing history of a controverisal drug. - NCBI
0.3 mg PO once daily in either continuous daily regimen or cyclic regimen (25 days on, 5 days off); adjusted PRN; use lowest dose that control symptoms; may be given daily if medical assessment warrants it 0.3-0.625 mg PO once daily in cyclic regimen (3 weeks on, 1 week off); may be titrated every 6-12 months; adjusted PRN; add progestin treatment should be added to maintain bone mineral density once skeletal maturity achieved Prophylaxis 0.3 mg PO once daily in cyclic regimen (25 days on, 5 days off); adjusted PRN based on clinical response; may be given daily if medical assessment warrants it; administer lowest effective dose May also be used in combination with medroxyprogesterone acetate 25 mg IV/IM; repeated in 6-12 hours PRN or 25 mg IV repeated q4hr for 24 hr; if no response after 2 doses, re-evaluate therapy Alternative regimen: 10-20 mg/day PO divided q4hr May administer low dose medroxyprogesterone acetate with therapy or following therapy Cyclic therapy: 25 days on, 5 days off; either 3 weeks on, 1 week off Known anaphylactic reaction or angioedema Known protein C, protein S, or antithrombin deficiency; other known thrombophilic disorders Active or history of breast cancer Arterial thromboembolic disease (stroke, MI), thrombopebitis, DVT/PE, thrombogenic valvular disease Liver disease, liver tumors Uncontrolled hypertension, diabetes mellitus with vascular involvement, jaundice with previous oral contraceptive use Estrogen-dependent neoplasia Undiagnosed abnormal vaginal bleeding Use caution in diabetes mellitus, hyperlipidemias, hypertension, hypothyroidism, advanced age, hepatic or renal impairment, uterine leiomyomata, porphyria, patients with defects of lipoprotein metabolism, hypertrlyceridemia, ovarian cancer, systemic lupus erhythematosus, exacerbation of endometriosis or other conditions, smoking, diseases exacerbated by fluid retention Discontinue if any of the following develop: Jaundice, sns of venous thromboembolism, visual problems (may cause contact lens intolerance), massive blood pressure increase, major surgery or prolonged immobilization occurring in 4 weeks, new mraine, depression, papilledema or retinal vascular lesions observed on examination Women with protein C or S deficiency (inherited thrombophilia), may have increased risk of venous thromboembolism Conditions exacerbated by fluid retention (asthma, epilepsy, mraines, cardiac or renal dysfunction) Risk of hypercalcemia in patients with breast cancer and bone metastases Increased risk of ovarian and endometrial cancer Long-term postmenopausal estrogen treatment has been associated with increased risk of breast cancer, MI, stroke, DVT/PE, and dementia Patients on warfarin or other oral anticoagulants: Estrogens increase thromboembolic risk; increase in anticoagulant dosage may be warranted Discontinue therapy if pancreatitis occurs; estrogen compounds generally associated with increased trlyceride levels Cases of anaphylaxis and angioedema have been reported; exogenous estrogens may exacerbate symptoms of angioedema in women with hereditary angioedema Reconstitute with 5 m L of diluent provided First withdraw air from vial, then add diluent slowly and aseptiy with gentle agitation Stable at 2-8°C for 60 days Do not use if agent darkens or precipitates The above information is provided for general informational and educational purposes only.
Rating: 88 / 100
Overall: 89 Rates